Clear cell ovarian carcinoma (CCOC) is generally associated with a favourable prognosis, however up to 30Â % of low-stage cases relapse within five years.
The benefit of adjuvant chemotherapy in early-stage disease (FIGO IA-IC1) remains uncertain.
This study aimed to identify molecular and immune markers associated with relapse in a well-characterized CCOC cohort.
